Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The initial step in the infection cycle of human immunodeficiency virus type 1 (HIV-1) involves binding of its surface glycoprotein gp 120 to the T lymphocyte CD4 antigen. CPF-DD is a low molecular weight inhibitor of HIV infectivity that inhibits gp 120 binding to CD4 in vitro (Finberg et al., Science 249, 287-291, 1990). We find, however, that the actions of CPF-DD are not limited to its ability to interfere with gp 120-CD4 binding; its predominant action is to remove the viral envelope from the underlying core. Subsequently the virions disintegrate. Most enveloped viruses tested were inhibited by CPF-DD, but the infectivity of noneneloped viruses was unaffected or only slightly reduced.

Type

Journal article

Journal

Virology

Publication Date

06/1992

Volume

188

Pages

537 - 544

Keywords

Animals, Antiviral Agents, Benzyl Compounds, CD4 Antigens, Cell Survival, Cells, Cultured, Dipeptides, HIV Envelope Protein gp120, HIV Infections, HIV-1, Humans, In Vitro Techniques, Lentivirus, Protein Binding, Retroviridae, Virion